Cargando…

Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have emerged as one of the most promising therapeutic options for patients with advanced cancer. The aim of the present study was to investigate the prognostic value of somatic mutations in mismatch repair (MMR) genes in metastatic cancers after ICI treatment, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yongping, Chen, Lin, Zhang, Shenli, Shu, Yimei, Qi, Qiufeng, Zhu, Ming, Peng, Yun, Ling, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405634/ https://www.ncbi.nlm.nih.gov/pubmed/32774500 http://dx.doi.org/10.3892/ol.2020.11888

Ejemplares similares

Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors
por: Hieggelke, Lena, et al.
Publicado: (2021)

The Somatic Mutational Landscape of Mismatch Repair Deficient Prostate Cancer
por: Fang, Bangwei, et al.
Publicado: (2023)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
por: Antill, Yoland, et al.
Publicado: (2021)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

DNA Mismatch Repair Gene Variant Classification: Evaluating the Utility of Somatic Mutations and Mismatch Repair Deficient Colonic Crypts and Endometrial Glands
por: Walker, Romy, et al.
Publicado: (2023)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies
por: Ryan, Neil A. J., et al.
Publicado: (2021)

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Mismatch Repair Status in Advanced Endometrial Cancer: Elective Affinities
por: Rizzo, Alessandro
Publicado: (2022)

Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors
por: Gambichler, T., et al.
Publicado: (2022)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
por: Su, Alan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials
por: Germani, Marco Maria, et al.
Publicado: (2021)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Patterns of germline and somatic mutations in 16 genes associated with mismatch repair function or containing tandem repeat sequences
por: Chang, Shih‐Ching, et al.
Publicado: (2019)

Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials
por: Cancanelli, Luca, et al.
Publicado: (2021)

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
por: Huyghe, Nicolas, et al.
Publicado: (2019)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
por: Tsai, Tsung-Han, et al.
Publicado: (2023)

New Phenotypes of Potato Co-induced by Mismatch Repair Deficiency and Somatic Hybridization
por: Rakosy-Tican, Elena, et al.
Publicado: (2019)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Preferential CEBP binding to T:G mismatches and increased C-to-T human somatic mutations
por: Yang, Jie, et al.
Publicado: (2021)

Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations
por: Li, Wenbin, et al.
Publicado: (2015)

DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression
por: Mäki-Nevala, Satu, et al.
Publicado: (2018)

Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2022)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status
por: Sawada, Kiyoka, et al.
Publicado: (2023)

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020)

Base excision repair AP endonucleases and mismatch repair act together to induce checkpoint-mediated autophagy
por: SenGupta, Tanima, et al.
Publicado: (2013)

DNA mismatch repair gene mutations in human cancer.
por: Peltomäki, P
Publicado: (1997)

Mismatch repair gene mutations and cancer risks: an update
por: Win, AK, et al.
Publicado: (2012)

Germline mutations in DNA repair and cell cycle checkpoint genes: consequential somatic gene alterations and genome instability
por: Ingvarsson, S
Publicado: (2003)

Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma
por: ÇAKIR, Emel, et al.
Publicado: (2021)

Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma
por: Giacomelli, Mauro, et al.
Publicado: (2023)

Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer
por: Huang, Qianpeng, et al.
Publicado: (2023)

NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES
por: Baig, Muhammed, et al.
Publicado: (2020)

Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies
por: Yan, Yu-Chuan, et al.
Publicado: (2022)

DNAH7 mutations benefit colorectal cancer patients receiving immune checkpoint inhibitors
por: Yang, Wenjuan, et al.
Publicado: (2022)

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †
por: de Glas, Nienke A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dbp3jdd54d1ridebjjqfn40gfm